tetano
Editor, Senior Moderator
Microbes Infect
. 2022 Oct 21;105062.
doi: 10.1016/j.micinf.2022.105062. Online ahead of print.
RNFPterostilbene effectively inhibits influenza A virus infection by promoting the type I interferon production
Wenjiao Wu[SUP] 1 [/SUP], Yilu Ye[SUP] 2 [/SUP], Yingyuan Zhong[SUP] 3 [/SUP], Xiukui Yan[SUP] 1 [/SUP], Jianguo Lin[SUP] 1 [/SUP], Jianxiang Qiu[SUP] 4 [/SUP], Shuwen Liu[SUP] 5 [/SUP], Zhixin Fang[SUP] 6 [/SUP]
Affiliations
Abstract
With the prevalence of novel strains and drug-resistant influenza viruses, there is an urgent need to develop effective and low-toxicity anti-influenza therapeutics. Regulation of the type I interferon antiviral response is considered an attractive therapeutic strategy for viral infection. Pterostilbene, a 3,5-dimethoxy analog of resveratrol, is known for its remarkable pharmacological activity. Here, we found that pterostilbene effectively inhibited influenza A virus infection and mainly affected the late stages of viral replication. A mechanistic study showed that the antiviral activity of pterostilbene might promote the induction of antiviral type I interferon and expression of its downstream interferon-stimulated genes during viral infection. The same effect of pterostilbene was also observed in the condition of polyinosinic-polycytidylic acid (poly I:C) transfection. Further study showed that pterostilbene revealed that pterostilbene interacted with influenza non-structural 1 (NS1) protein, inhibit RIG-I ubiquitination mediated degradation of RIG-I and activates the downstream antiviral pathway, orchestrating an antiviral state against influenza virus in the cell. Taken together, pterostilbene could be a promising anti-influenza agent for future antiviral drug exploitation and compounds with similar structures may provide new options for the development of novel inhibitors against influenza A virus (IAV).
Keywords: Influenza A virus; NS1; Pterostilbene; RIG-I; Type I interferon.
. 2022 Oct 21;105062.
doi: 10.1016/j.micinf.2022.105062. Online ahead of print.
RNFPterostilbene effectively inhibits influenza A virus infection by promoting the type I interferon production
Wenjiao Wu[SUP] 1 [/SUP], Yilu Ye[SUP] 2 [/SUP], Yingyuan Zhong[SUP] 3 [/SUP], Xiukui Yan[SUP] 1 [/SUP], Jianguo Lin[SUP] 1 [/SUP], Jianxiang Qiu[SUP] 4 [/SUP], Shuwen Liu[SUP] 5 [/SUP], Zhixin Fang[SUP] 6 [/SUP]
Affiliations
- PMID: 36280208
- DOI: 10.1016/j.micinf.2022.105062
Abstract
With the prevalence of novel strains and drug-resistant influenza viruses, there is an urgent need to develop effective and low-toxicity anti-influenza therapeutics. Regulation of the type I interferon antiviral response is considered an attractive therapeutic strategy for viral infection. Pterostilbene, a 3,5-dimethoxy analog of resveratrol, is known for its remarkable pharmacological activity. Here, we found that pterostilbene effectively inhibited influenza A virus infection and mainly affected the late stages of viral replication. A mechanistic study showed that the antiviral activity of pterostilbene might promote the induction of antiviral type I interferon and expression of its downstream interferon-stimulated genes during viral infection. The same effect of pterostilbene was also observed in the condition of polyinosinic-polycytidylic acid (poly I:C) transfection. Further study showed that pterostilbene revealed that pterostilbene interacted with influenza non-structural 1 (NS1) protein, inhibit RIG-I ubiquitination mediated degradation of RIG-I and activates the downstream antiviral pathway, orchestrating an antiviral state against influenza virus in the cell. Taken together, pterostilbene could be a promising anti-influenza agent for future antiviral drug exploitation and compounds with similar structures may provide new options for the development of novel inhibitors against influenza A virus (IAV).
Keywords: Influenza A virus; NS1; Pterostilbene; RIG-I; Type I interferon.